Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Research Article

Substituted 3-R-2,8-Dioxo-7,8-dihydro-2H-pyrrolo[1,2-a][1,2,4] triazino [2,3-c]quinazoline-5a(6H)carboxylic Acids and their Salts – a Promising Class of Anti-inflammatory Agents

Author(s): Viktor Stavytskyi*, Oleksii Antypenko, Inna Nosulenko, Galyna Berest, Oleksii Voskoboinik and Sergiy Kovalenko

Volume 20, Issue 1, 2021

Published on: 05 May, 2020

Page: [75 - 88] Pages: 14

DOI: 10.2174/1871523019666200505073232

Price: $65

Abstract

Background: Computer-aided drug design is among the most effective methods of medicinal chemistry. The above mentioned approach is used for the purposeful search of antiinflammatory agents among quinazoline condensed derivatives.

Objective: The study aimed to conduct a purposeful synthesis of novel 3-R-2,8-dioxo-7,8-dihydro- 2H-pyrrolo[1,2-a][1,2,4]triazino[2,3-c]quinazoline-5a(6H)carboxylic acids and their salts as promising anti-inflammatory agents, evaluate their structure by physicochemical methods and establish their anti-inflammatory activity.

Methods: The structures of target compounds were proposed due to their structure similarity to existing drugs and experimental agents with anti-inflammatory activities. The features of the synthesized compounds structures were evaluated by IR-, NMR spectroscopy and chromatography-mass spectrometry and discussed in detail. Probable molecular mechanisms of activity were predicted by molecular docking. The anti-inflammatory activity was determined by their ability to reduce the formalin- and carrageenan-induced paw edema in rats.

Results: It was found that the condensation of 3-(2-aminophenyl)-6-R-1,2,4-triazin-5(2H)ones with 2-oxoglutaric acid yielded 3-R-2,8-dioxo-7,8-dihydro-2H-pyrrolo[1,2-a][1,2,4]triazino[2,3-c]quinazoline- 5a(6H)carboxylic acids which may be considered as a promising anti-inflammatory agent. An in silico study showed that the obtained compounds revealed affinity to the molecular targets and corresponded to the drug-like criteria. Additionally docking study allowed to estimate the nature of interactions between synthesized compounds and molecular targets. The in vivo experiments showed that the obtained compounds demonstrated significant anti-inflammatory activity comparable or higher than the activity of the reference drug Diclofenac.

Conclusion: The developed and implemented search strategy of the anti-inflammatory agents was justified. 3-R-2,8-dioxo-7,8-dihydro-2H-pyrrolo[1,2-a][1,2,4]triazino[2,3-c]quinazoline5a(6H)carboxylic acids possessed the anti-inflammatory activity and additional introduction of fluorine atoms in position 11 or 12 of the heterocyclic system led to amplification of this activity.

Keywords: Anti-inflammatory activity, drug design, 3-(2-aminophenyl)-6-R-1, 2, 4-triazin-5(2H)ones, pyrrolo[1, 2-a][1, 2, 4] triazino[2, 3-c]quinazolines, molecular docking, SAR.

Graphical Abstract
[1]
Jeremy, I.L.; Stefan, L. Anti-inflammatory drug discovery. RSC Drug Discovery Series No. 26, 2012.
[2]
Poddighe, D.; Brambilla, I.; Licari, A.; Marseglia, G.L. Ibuprofen for pain control in children: New value for an old molecule. Pediatr. Emerg. Care, 2019, 35(6), 448-453.
[http://dx.doi.org/10.1097/PEC.0000000000001505] [PMID: 29912084]
[3]
Eccleston, C.; Cooper, T.E.; Fisher, E.; Anderson, B.; Wilkinson, N.M. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents. Cochrane Database Syst. Rev., 2017, 2(8), CD012537.
[4]
Warner, T.D.; Mitchell, J.A. Cyclooxygenases: New forms, new inhibitors, and lessons from the clinic. FASEB J., 2004, 18(7), 790-804.
[http://dx.doi.org/10.1096/fj.03-0645rev] [PMID: 15117884]
[5]
Balabanova, R.M. Cardiovascular effects of selective COX-2 inhibitors in rheumatic diseases. Sovremennaya revmatologiya, 2010, 288-293.
[6]
Feuba, D.A. Gastrointestinal safety and tolerability of non selective nonsteroidal antiinflammatory agents and cycloxygenase 2 selective inhibitors. Cleve. Clin. J. Med., 2002, 69, 31-39.
[7]
Dey, I.; Lejeune, M.; Chadee, K. Prostaglandin E2 receptor distribution and function in the gastrointestinal tract. Br. J. Pharmacol., 2006, 149(6), 611-623.
[http://dx.doi.org/10.1038/sj.bjp.0706923] [PMID: 17016496]
[8]
Hajduk, P.J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov., 2007, 6(3), 211-219.
[http://dx.doi.org/10.1038/nrd2220] [PMID: 17290284]
[9]
Erlanson, D.A. Introduction to fragment-based drug discovery. Top. Curr. Chem., 2012, 317, 1-32.
[PMID: 21695633]
[10]
Kulkarni, S.K.; Singh, V.P. Licofelone--a novel analgesic and anti-inflammatory agent. Curr. Top. Med. Chem., 2007, 7(3), 251-263.
[http://dx.doi.org/10.2174/156802607779941305] [PMID: 17305568]
[11]
Macario, A.; Lipman, A.G. Ketorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: A systematic review of efficacy, side effects, and regulatory issues. Pain Med., 2001, 2(4), 336-351.
[http://dx.doi.org/10.1046/j.1526-4637.2001.01043.x] [PMID: 15102238]
[12]
Yakubovska, V.V.; Seredinska, N.M.; Voskoboynik, O.Yu.; Stepanyuk, G.I.; Kovalenko, S.I. Purposeful search and characteristic of anti-inflammatory activity of sodium (3-R-2-оxo-2Н-[1,2,4]triazino[2,3-c]quinazolin-6-yl)alkylcarboxylates and their halogen containing analogues. Aktualni pitannya farmacevtichnoyi i medichnoyi nauki ta praktiki, 2016, 1(20), 60-66.
[13]
Kolomoets, O.; Voskoboynik, O.; Antypenko, O.; Berest, G.; Nosulenko, I.; Palchikov, V.; Karpenko, O.; Kovalenko, S. Desing, synthesis and anti-inflammatory activity of dirivatives 10-R-3-aryl-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-2-ones of spiro-fused cyclic frameworks. Acta Chim. Slov., 2017, 64(4), 902-910.
[http://dx.doi.org/10.17344/acsi.2017.3575] [PMID: 29318300]
[14]
Sergeieva, T.Yu.; Voskoboynik, O.Yu.; Okovytyy, S.I.; Kovalenko, S.I.; Shishkina, S.V.; Shishkin, O.V.; Leszczynski, J. Hydrazinolysis of 3-R-[1,2,4]triazino[2,3-c]quinazolin-2-ones. Synthetic and theoretical aspects. J. Phys. Chem. A, 2014, 118(10), 1895-1905.
[http://dx.doi.org/10.1021/jp4052616] [PMID: 24533576]
[15]
Protein Data Bank. http://www.rcsb.org/pdb/home/home.do (Accessed December 5, 2019)
[16]
MarvinSketch version 19.24, ChemAxon, http://www. chemaxon.com
[17]
Trott, O.; Olson, A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem., 2010, 31(2), 455-461.
[PMID: 19499576]
[18]
Discovery Studio Visualizer v19.1.018287. Accelrys Software Inc, 1986.
[20]
European convention for the protection of vertebrate animal used for experimental and other scientific purposes, Council of Europe, Strasbourg 1986.
[21]
Fehrenbacher, J.C.; Vasko, M.R.; Duarte, D.B. Models of inflammation: carrageenan- or complete freund’s adjuvant (cfa)-induced edema and hypersensitivity in the rat. Curr. Protocols Pharmacol., 2012, 56(1), 541-547.
[22]
Lapach, S.N.; Chubenko, A.V.; Babich, P.N. The effect of ultra low concentrations of some biologically active substances on the aerobic respiration. Cell bio, 2001, 10, 408.
[23]
Khanapure, S.P.; Garvey, D.S.; Janero, D.R.; Letts, L.G. Eicosanoids in inflammation: biosynthesis, pharmacology, and therapeutic frontiers. Curr. Top. Med. Chem., 2007, 7(3), 311-340.
[http://dx.doi.org/10.2174/156802607779941314] [PMID: 17305573]
[24]
Dennis, E.A.; Norris, P.C. Eicosanoid storm in infection and inflammation. Nat. Rev. Immunol., 2015, 15(8), 511-523.
[http://dx.doi.org/10.1038/nri3859] [PMID: 26139350]
[25]
Meyer, M.C.; Rastogi, P.; Beckett, C.S.; McHowat, J. Phospholipase A2 inhibitors as potential anti-inflammatory agents. Curr. Pharm. Des., 2005, 11(10), 1301-1312.
[http://dx.doi.org/10.2174/1381612053507521] [PMID: 15853686]
[26]
Auffinger, P.; Hays, F.A.; Westhof, E.; Ho, P.S. Halogen bonds in biological molecules. Proc. Natl. Acad. Sci. USA, 2004, 101(48), 16789-16794.
[http://dx.doi.org/10.1073/pnas.0407607101] [PMID: 15557000]
[27]
Stavytskyi, V.; Voskoboinik, O.; Kazunin, M.; Nosulenko, I.; Shishkina, S.; Kovalenko, S. Substituted pyrrolo[1,2-a][1,2,4]triazolo-([1,2,4]triazino-)[c]quinazoline-4a(5a)-propanoic acids: synthesis, spectral characteristics and anti-inflammatory activity. Voprosy khimii i khimicheskoi tekhnologii, 2020, 1, 61-70.
[28]
Voskoboynik, O.Yu.; Kolomoetsa, O.S.; Antypenko, O.M.; Zhernova, G.O.; Nosulenko, I.S.; Berest, G.G.; Shvets, V.M.; Kovalenko, S.I. Synthesis and hypolipidemic activity of new 6,6-disubstituted 3-R-6,7-dihydro-2H-[1,2,4]triazino[2,3-c]quinazolin-2-ones. J. Heterocycl. Chem., 2017, 35(1), 318-325.
[http://dx.doi.org/10.1002/jhet.3054]
[29]
Breitmaier, E. Structure elucidation by NMR in organic chemistry: A practical guide., (3rd ed.), 2002, 270.
[http://dx.doi.org/10.1002/0470853069]
[30]
Müller, K.; Faeh, C.; Diederich, F. Fluorine in pharmaceuticals: looking beyond intuition. Science, 2007, 317(5846), 1881-1886.
[http://dx.doi.org/10.1126/science.1131943] [PMID: 17901324]

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy